Prestige Biologics KRX:334970KOSDAQ
프레스티지바이오로직스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked4since Sep 11
In Q1 2026, Prestige Biologics reported revenue of ₩2.3bn, down 34.8% year on year, and an operating loss of ₩16.3bn. Prestige Biologics (프레스티지바이오로직스) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals Split / consolidation 4 quarters of losses Screener
Prestige Biologics quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q1 2026 | ₩2.3bn | -34.8% | −₩16.3bn | −₩14.6bn |
| Q4 2025 | ₩8.9bn | +194.5% | −₩9.7bn margin −109.5% | −₩8.3bn |
| Q3 2025 | ₩1.2bn | +241.4% | −₩13.6bn | −₩12.9bn |
| Q2 2025 derived | ₩5.7bn | – | −₩4.2bn margin −73.6% | ₩438m |
| Q1 2025 | ₩3.5bn | +444.9% | −₩7.3bn margin −208.9% | −₩7.5bn |
| Q4 2024 | ₩3.0bn | – | −₩12.9bn | −₩13.9bn |
| Q3 2024 | ₩342m | – | −₩9.3bn | −₩6.5bn |
| Q2 2024 derived check units | −₩135m | – | −₩1.9bn | −₩5.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Prestige Biologics top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.